Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Oil Prices Slide as OPEC, IEA Cut 2026 Demand Forecasts 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Japan Government Backs Earlier BOJ Rate Hike as Inflation Pressures Build 
ADNOC Gas Targets Up to $4B Profit in 2026 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Add as a preferred source on Google
LG Chem Ltd. has finally completed completes acquisition of AVEO Pharmaceuticals inc., and this was announced last week. The South Korean chemical firm is aiming to become one of the top 30 pharma companies in the world, and the acquisition is the first step to achieving the goal.
LG Chem invested around $571 million in its LG Chem Life Science Innovation Center in the United States for the takeover of the US-based firm. As per Yonhap News Agency, the deal was first announced in October 2022, and the following December, the U.S. antitrust watchdog handed its approval for the deal to go ahead.
AVEO Pharma’s board of directors proceeded to accept LG Chem's offer in the second week of January. Thus, the transaction was completed. With the completion, the American pharma firm is now listed as a second-tier subsidiary of LG Chem.
AVEO Pharmaceuticals was founded in 2002 and was listed on Nasdaq in 2010. Its sales reached KRW130 billion or about $105 million last year, and this year, it was predicted to earn KRW210 billion.
LG Chem revealed that since the company is already one of its affiliates, it will be transferring its anti-cancer drug business to AVEO. This is also a strategic move on LG Chem’s part as it is also aiming to boost its production in the U.S. Moreover, the Korean firm will be investing KRW2 trillion in the research and development (R&D) bio business by 2027 and will release at least four new drugs in markets overseas.
“The merger extends LG Chem Life Sciences’ commercial footprint to the U.S., diversifies our pipeline and advances our combined capabilities with AVEO, accelerating our ability to develop, commercialize and acquire world-class cancer therapies,” LG Chem Life Sciences president, Dr. Son Jeewoong, said in a press release. “We look forward to working closely with AVEO’s experienced and talented team as we welcome them to the LG Chem family.”
AVEO’s president and chief executive officer, Michael Bailey, added, “This transaction delivered significant value to our shareholders and AVEO is now positioned to benefit from the support and resources of LG Chem as we advance our mission of improving the lives of patients with cancer.”
